Home   About this service   Get the news  
+32 2 743 34 03

 
UCB [BE0003739530 / UCB]

UCB Media Room: Transparency Notification

INFORMATION REGLEMENTEE


[24/07/2018 | 20:00]

Transparency notifications BlackRock, Inc.

  • 2 notifications referring to situation on 18 July and 19 July 2018
  • Threshold crossed: 5%
  • Latest holding: 5.00%

Brussels (Belgium), 24 July 2018 – 20:00 (CEST) – regulated information

1. Summary of the notifications
Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received 2 transparency notifications from BlackRock, Inc. (having its registered office at 55 East 52nd Street, New York, NY, 10055, U.S.A.), dated 19 July and 20 July 2018 respectively.

In the first notification BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and a disposal of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has decreased and has crossed downwards the 5% threshold on 18 July 2018. 

In the second notification, BlackRock, Inc. has notified that, following an acquisition of UCB shares with voting rights and a disposal of equivalent financial instruments by its affiliates, its total holding in UCB SA/NV has increased and has reached the 5% threshold on 19 July 2018. 

On 18 July 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 012 183 UCB shares with voting rights (versus 8 982 056 shares in its previous notification dated 9 July 2018), representing 4.63% of the total number of shares issued by the company (194 505 658) (versus 4.62% in the notification dated 9 July 2018) as well as 672 027 equivalent financial instruments (versus          803 011 in its previous notification dated 9 July 2018) representing 0.35% of the total number of shares issued by the company (versus 0.41% in the notification dated 9 July 2018).

On 19 July 2018, BlackRock, Inc. (taking into account the holding of its affiliates) owned 9 090 707 UCB shares with voting rights, representing 4.67% of the total number of shares issued by the company, as well as 636 167 equivalent financial instruments, representing 0.33% of the total number of shares issued by the company.

2. Content of the notifications
2.1 The information mentioned hereafter was identical in both notifications:

  • Reason for the notification: Acquisition or disposal of voting securities or voting rights.
  • Notification by: A parent undertaking or a controlling person.
  • Threshold crossed (in %): 5%
  • Denominator: 194 505 658.
  • Chain of controlled undertakings through which the holding is effectively held:

Please see the full chain of control in a PDF which is sent separately to this notification.

2.2 The first transparency notification dated 19 July 2018 included the following specific information:

  • Persons subject to the notification requirement: 

  • Date on which the threshold is crossed: 18 July 2018.
  • Notified details:

 

  • Additional information

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going below 5%.

2.3. The second transparency notification dated 20 July 2018 includes the following specific information:

  • Persons subject to the notification requirement: 

  • Date on which the threshold is crossed: 19 July 2018.
  • Notified details:

 

 

  • Additional information: 

The disclosure obligation arose due to total holding in voting rights for BlackRock, Inc. going above 5%.

3. Further information 

This press release and the detailed transparency notification are available on UCB SA/NV’s website via the following link.
An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV’s website via the following link.


Investor Relations
Antje Witte          
Investor Relations, UCB
T +32.2.559.94.14 antje.witte@ucb.com
Isabelle Ghellynck,
 Investor Relations, UCB
T+32.2.559.9588, isabelle.ghellynck@ucb.com 

About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 7 500 people in approximately 40 countries, the company generated revenue of € 4.5 billion in 2017. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news
 

Open PDF of "Transparency Notification July 24, 2018 ENG"

Open PDF of "Transparency Notification July 24, 2018 FR"

Open PDF of "Transparency Notification July 24, 2018 Nl"

 



If you would rather not receive future communications from UCB SA, let us know by clicking here.
UCB SA, Allée de la Recherche, 60 ., Brussels, . B - 1070 Belgium